BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced that its lead product candidate, Bria-IMT™, will be featured in three poster presentations at the 2022 San Antonio Breast Cancer Symposium from December 6-10. The presentations aim to share clinical findings with healthcare professionals treating advanced breast cancer patients who are unresponsive to existing therapies. The posters will be displayed at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Copies will be available online after the event.
- BriaCell's Bria-IMT™ is receiving exposure at a significant oncology conference.
- The participation indicates the company's commitment to addressing advanced breast cancer.
- None.
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
“Our mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients,” stated Dr. Bill Williams, BriaCell’s President & CEO.
All poster presentations will be held at Hall 1, Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 U.S.A. Details on the poster presentations are as follows:
Poster ID: P1-05-28
Date: Tuesday, December 6, 2022
Time: 5:00 PM - 6:15 PM
Poster ID: P3-07-12
Poster ID: P3-06-08
Date: Wednesday, December 7, 2022
Time: 5:00 PM - 6:15 PM
Following the presentations, copies of the posters will be posted on https://briacell.com/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
What is BriaCell's lead product candidate featured at the San Antonio Breast Cancer Symposium?
When will BriaCell present its clinical findings?
Where is the 2022 San Antonio Breast Cancer Symposium being held?
What are the poster presentation IDs for BriaCell at the symposium?
How can I access BriaCell's poster presentations after the event?
